Literature DB >> 15153521

TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells.

Konstantinos A Papadakis1, John L Prehn, Carol Landers, Qiwei Han, Xia Luo, Stephanie C Cha, Ping Wei, Stephan R Targan.   

Abstract

TL1A, a recently described TNF-like cytokine that interacts with DR3, costimulates T cells and augments anti-CD3 plus anti-CD28 IFN-gamma production. In the current study we show that TL1A or an agonistic anti-DR3 mAb synergize with IL-12/IL-18 to augment IFN-gamma production in human peripheral blood T cells and NK cells. TL1A also enhanced IFN-gamma production by IL-12/IL-18 stimulated CD56(+) T cells. When expressed as fold change, the synergistic effect of TL1A on cytokine-induced IFN-gamma production was more pronounced on CD4(+) and CD8(+) T cells than on CD56(+) T cells or NK cells. Intracellular cytokine staining showed that TL1A significantly enhanced both the percentage and the mean fluorescence intensity of IFN-gamma-producing T cells in response to IL-12/IL-18. The combination of IL-12 and IL-18 markedly up-regulated DR3 expression in NK cells, whereas it had minimal effect in T cells. Our data suggest that TL1A/DR3 pathway plays an important role in the augmentation of cytokine-induced IFN-gamma production in T cells and that DR3 expression is differentially regulated by IL-12/IL-18 in T cells and NK cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15153521     DOI: 10.4049/jimmunol.172.11.7002

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  65 in total

1.  Constitutive TL1A expression under colitogenic conditions modulates the severity and location of gut mucosal inflammation and induces fibrostenosis.

Authors:  Robert Barrett; Xiaolan Zhang; Hon Wai Koon; Michelle Vu; Jyh-Yau Chang; Nicole Yeager; Mary Ann Nguyen; Kathrin S Michelsen; Dror Berel; Charalabos Pothoulakis; Stephan R Targan; David Q Shih
Journal:  Am J Pathol       Date:  2011-12-02       Impact factor: 4.307

2.  TL1A selectively enhances IL-12/IL-18-induced NK cell cytotoxicity against NK-resistant tumor targets.

Authors:  Stephanie C Heidemann; Valerie Chavez; Carol J Landers; Torsten Kucharzik; John L Prehn; Stephan R Targan
Journal:  J Clin Immunol       Date:  2010-03-27       Impact factor: 8.317

3.  Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation.

Authors:  Taylor H Schreiber; Dietlinde Wolf; Matthew S Tsai; Jackie Chirinos; Vadim V Deyev; Louis Gonzalez; Thomas R Malek; Robert B Levy; Eckhard R Podack
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

4.  TL1A: a mediator of gut inflammation.

Authors:  Howard A Young; Michael G Tovey
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-22       Impact factor: 11.205

5.  On death receptor 3 and its ligands….

Authors:  Eddie C Y Wang
Journal:  Immunology       Date:  2012-09       Impact factor: 7.397

Review 6.  TL1A and DR3, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation.

Authors:  Françoise Meylan; Arianne C Richard; Richard M Siegel
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

7.  TLR8-mediated activation of human monocytes inhibits TL1A expression.

Authors:  Masayuki Saruta; Kathrin S Michelsen; Lisa S Thomas; Qi T Yu; Carol J Landers; Stephan R Targan
Journal:  Eur J Immunol       Date:  2009-08       Impact factor: 5.532

8.  TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation.

Authors:  Hidetoshi Takedatsu; Kathrin S Michelsen; Bo Wei; Carol J Landers; Lisa S Thomas; Deepti Dhall; Jonathan Braun; Stephan R Targan
Journal:  Gastroenterology       Date:  2008-05-07       Impact factor: 22.682

9.  Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells.

Authors:  David Q Shih; Lola Y Kwan; Valerie Chavez; Offer Cohavy; Rivkah Gonsky; Elmer Y Chang; Christopher Chang; Charles O Elson; Stephan R Targan
Journal:  Eur J Immunol       Date:  2009-11       Impact factor: 5.532

10.  Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells.

Authors:  Daniel A Vallera; Bin Zhang; Michelle K Gleason; Seunguk Oh; Louis M Weiner; Dan S Kaufman; Valarie McCullar; Jeffrey S Miller; Michael R Verneris
Journal:  Cancer Biother Radiopharm       Date:  2013-04-23       Impact factor: 3.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.